Sanofi Profit Beats Estimates as Blockbuster Drug Advances
- Best-seller Dupixent powered growth, may get new forecast
- Drugmaker reiterates earnings guidance for full year
This article is for subscribers only.
Sanofi’s profit rose in the first quarter, exceeding estimates as the French drugmaker’s blockbuster therapy Dupixent gained market share.
Earnings per share reached €2.16 ($2.39) excluding some items, Sanofi said Thursday. That topped analysts’ €2 estimate. The shares rose as much as 2.3% in early Paris trading.